Oncology
Biliary Cancer
0
Pipeline Programs↗
6
Active Trials↗
3
Companies Involved↗
Biliary Cancer is an early-stage landscape with 0 programs across 3 companies. The most active players are AbGenomics B.V Taiwan Branch, Daiichi Sankyo, Spectrum Pharmaceuticals, Inc.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
27
clinical trials
Completed13 · 48%
Terminated7 · 26%
Not yet recruiting2 · 7%
Active, not recruiting2 · 7%
Recruiting2 · 7%
Withdrawn1 · 4%
Clinical Trials
Trial Activity
27 trials
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Active, not recruiting·—·Phase 1/2·NCT03337087·18 enrolled
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
Not yet recruiting·—·Phase 4·NCT06818773·35 enrolled
Pembrolizumab and GM-CSF in Biliary Cancer
Completed·—·Phase 2·NCT02703714·42 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)